[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354109-105":59,"doc-detail-354109-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","feasibility-of-decentralized-real-world-monitoring-of-sars-cov-2-booster-vaccines-and-covid-19-outcomes-in-myeloma","Feasibility of decentralized real-world monitoring of SARS-CoV-2 booster vaccines and COVID-19 outcomes in myeloma","","Feasibility of a decentralized, proof-of-concept real-world study was evaluated in patients with multiple myeloma through the COSMIC program. Participants consented and used an electronic study portal to authorize electronic health record data collection and complete patient-reported outcomes at baseline, day 30, and day 180, supported by monthly site best-practice sharing. In 201 enrolled patients from 8 sites over 4 months, data completion remained high and health-related quality of life showed no significant time differences.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/feasibility-of-decentralized-real-world-monitoring-of-sars-cov-2-booster-vaccines-and-covid-19-outcomes-in-myeloma/354109/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/feasibility-of-decentralized-real-world-monitoring-of-sars-cov-2-booster-vaccines-and-covid-19-outcomes-in-myeloma/354109.png","ImageObject",300,407,{"name":92,"@type":93},"Bintang","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the main goal of the COSMIC decentralized study?","Question",{"text":112,"@type":113},"To demonstrate feasibility of decentralized evidence generation by enrolling multiple myeloma patients, collecting electronic health record data, and capturing patient-reported outcomes through a web portal.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were participants recruited and followed in the study?",{"text":117,"@type":113},"Clinicians at participating sites facilitated recruitment, and participants completed patient-reported outcomes at baseline, day 30, and day 180 while consenting to electronic health record data collection.",{"name":119,"@type":110,"acceptedAnswer":120},"What enrollment and data-completion results support feasibility?",{"text":121,"@type":113},"The study rapidly consented 201 patients from 8 sites over 4 months, with patient-reported data completion of 97% at baseline, 81% at 1 month, and 79% at 6 months.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},354109,1791045361,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},962085564381,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","REGULAR ARTICLE  \nFeasibility of decentralized real-world monitoring of SARS-CoV-2 booster vaccines and COVID-19 outcomes in myeloma  \nWilliam A. Wood, 1 Shaji K. Kumar,2 Emily A. Semmel,3 Shandra James,3 Mark A. Schroeder,4 David J. Chung,5 Aaron Rosenberg,6 Jeffrey Zonder,7 Samuel Rubinstein, 1 Anita D’Souza,8 Thomas Martin,9 Ajai Chari,9 Ravi Vij,4 Ajay K. Nooka, 10 Kenneth C. Anderson, 11 Donna S. Neuberg, 11 Shambavi Richard, 12 Kathleen Torres,(formerly Hewitt),3 Brendan M. Weiss, 13 Levi Pederson,2 Andriy Derkach,5 Susan Geyer,2 and Saad Z. Usmani5  \n1 Division of Hematology, The University of North Carolina at Chapel Hill, Chapel Hill, NC; 2 Mayo Clinic, Rochester, MN; 3ASH Research Collaborative, Washington, DC; 4 Division of Oncology, Washington University School of Medicine in St. Louis, St. Louis, MO; 5 Memorial Sloan Kettering Cancer Center, New York, NY; 6 Division of Hematology and Oncology, University of California, Davis, Sacramento, CA; 7 Karmanos Cancer Institute, Detroit, MI; 8 Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI; 9 Hematology, Blood and Marrow Transplant, and Cellular Therapy Program, University of California, San Francisco, San Francisco, CA;  \n10Winship Cancer Institute of Emory University, Atlanta, GA; 11 Dana-Farber Cancer Institute, Boston, MA; 12 Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY; and 13 Moderna, Inc, Cambridge, MA  \nKey Points  \n• Feasibility is shown for decentralized data collection in a diverse, real-world multiple myeloma patient cohort.  \n• By using adecentralized design and web portal, site burden was minimized, and individuals aged  \n29 to 93 years successfully participated.  \nPatients with multiple myeloma have an elevated risk of severe complications from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; COVID-19) infection. To demonstrate proof of concept for a pandemic preparedness and response network, the American Society of Hematology Research Collaborative Multiple Myeloma Program developed a prospective, decentralized study within a site-based provider network. In the COVID-19 outcomes in myeloma and the impact of vaccines (COSMIC) study, patients provided consent, permitted electronic health record data collection, completed patientreported outcomes at baseline, day 30, and day 180 through an electronic study portal, and were compensated for participation. Clinicians at participating sites facilitated study recruitment and shared best practices monthly to accelerate study execution. The COSMIC study rapidly consented 201 patients from 8 participating sites over 4 months (22 January 2024 through 17 May 2024) . Consented participants were 30 to 93 years old, with a median age of 67; 46% were female, 69% were non-Hispanic White, 17% were non-Hispanic Black, and 8% were Hispanic/Latino. Patient-reported data completion was 97% at baseline, 81% at 1 month, and 79% at 6 months. At baseline, 55% of patients reported a history of COVID- 19 infection and had received a median of 4 SARS-CoV-2 vaccines. For all patients, there were an additional 18 COVID-19 infections and 57 vaccines received during the 6-month observation period. There were no significant differences in health-related quality of life over time or by history of COVID-19 infection. COSMIC demonstrates the feasibility of an innovative evidence generation strategy to drive rapid accrual of patients to address an evolving area of need. This trial was registered [at](at www.clinicaltrials.gov)[ www.clinicaltrials.gov](at www.clinicaltrials.gov) as \\#NCT05831787 .  \nSubmitted 31 October 2025; accepted 28 January 2026; prepublished online on Blood Advances First Edition 24 February 2026. [https://doi.org/10.1182/](https://doi.org/10.1182/)[ ](https://doi.org/10.1182/)[bloodadvances.2025018963](bloodadvances.2025018963.)[.](bloodadvances.2025018963.)  \nThe deidentified data used in this study may be available for additi","cbCaicGV6TtV5KJ7","https://ap.wps.com/l/cbCaicGV6TtV5KJ7","pdf",521295,"English","# Key Points\n# Introduction","[{\"question\":\"What was the main goal of the COSMIC decentralized study?\",\"answer\":\"To demonstrate feasibility of decentralized evidence generation by enrolling multiple myeloma patients, collecting electronic health record data, and capturing patient-reported outcomes through a web portal.\"},{\"question\":\"How were participants recruited and followed in the study?\",\"answer\":\"Clinicians at participating sites facilitated recruitment, and participants completed patient-reported outcomes at baseline, day 30, and day 180 while consenting to electronic health record data collection.\"},{\"question\":\"What enrollment and data-completion results support feasibility?\",\"answer\":\"The study rapidly consented 201 patients from 8 sites over 4 months, with patient-reported data completion of 97% at baseline, 81% at 1 month, and 79% at 6 months.\"}]","Feasibility of decentralized real-world monitoring of SARS-CoV-2 booster vaccines and COVID-19 outcomes in myeloma | PDF",1790109002,23,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/68f77161b9db9b8445d28c0d18271692.webp",983,1296,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f872c71a77a93c6db2ddd0ee2330418f.webp",982,1294,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/238e3b4716d1b6fa14b6e2f929a645ef.webp",981,1293,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2d9b40c96019ea8d731f5ea32dff59ec.webp",980,1292]